Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in 
Non-small Cell Lung Cancer

Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in 
Non-small Cell Lung Cancer

Immune checkpoint inhibitors (ICI) have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). Biomarkers are essential for guiding precision immunotherapy. Tissue-based programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) are currently widely u...

Full description

Bibliographic Details
Main Authors: Peng WANG, Chuanhao TANG, Jun LIANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-07-01
Series:Chinese Journal of Lung Cancer
Subjects:
blood biomarkers
immmune checkpoint inhibitors
lung neoplasms
immunotherapy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.24

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.24

Similar Items